AR056800A1 - Uso de inhibidores de la pde iii para el tratamiento de la isuficiencia cardiaca asintomatica ( oculta ) - Google Patents

Uso de inhibidores de la pde iii para el tratamiento de la isuficiencia cardiaca asintomatica ( oculta )

Info

Publication number
AR056800A1
AR056800A1 ARP060104928A ARP060104928A AR056800A1 AR 056800 A1 AR056800 A1 AR 056800A1 AR P060104928 A ARP060104928 A AR P060104928A AR P060104928 A ARP060104928 A AR P060104928A AR 056800 A1 AR056800 A1 AR 056800A1
Authority
AR
Argentina
Prior art keywords
hidden
isufficiency
asydomatic
cardiac
treatment
Prior art date
Application number
ARP060104928A
Other languages
English (en)
Spanish (es)
Inventor
Christian Troetschel
Andrea Wollmar
Rainer Kleemann
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37744668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR056800(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR056800A1 publication Critical patent/AR056800A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP060104928A 2005-11-14 2006-11-10 Uso de inhibidores de la pde iii para el tratamiento de la isuficiencia cardiaca asintomatica ( oculta ) AR056800A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05110689 2005-11-14

Publications (1)

Publication Number Publication Date
AR056800A1 true AR056800A1 (es) 2007-10-24

Family

ID=37744668

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104928A AR056800A1 (es) 2005-11-14 2006-11-10 Uso de inhibidores de la pde iii para el tratamiento de la isuficiencia cardiaca asintomatica ( oculta )

Country Status (13)

Country Link
US (2) US20070112010A1 (https=)
EP (2) EP3210605A1 (https=)
JP (1) JP5312034B2 (https=)
CN (2) CN101309685A (https=)
AR (1) AR056800A1 (https=)
AU (1) AU2006310997B2 (https=)
CA (1) CA2629367C (https=)
DK (1) DK1951227T3 (https=)
ES (1) ES2631879T3 (https=)
HU (1) HUE033546T2 (https=)
PL (1) PL1951227T3 (https=)
TW (1) TW200735874A (https=)
WO (1) WO2007054514A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
FI20040674A0 (fi) 2004-05-12 2004-05-12 Orion Corp Menetelmä tromboembolisten sairauksien estoon
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
CA2723372A1 (en) * 2008-05-05 2009-11-12 University Of Rochester Methods and compositions for the treatment or prevention of pathological cardiac remodeling and heart failure
EP2370070B9 (en) 2008-11-25 2014-04-23 Boehringer Ingelheim Vetmedica GmbH Pimobendan for use in the treatment of hypertrophic cardiomyopathy in cats.
NL1037569C2 (en) * 2009-12-18 2011-06-21 Eurovet Animal Health B V Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use.
HUE060093T2 (hu) * 2012-03-15 2023-01-28 Boehringer Ingelheim Vetmedica Gmbh Gyógyszerészeti tablettakészítmény az állatgyógyászati ágazat számára, eljárás annak elõállítására és annak alkalmazása
HUE054186T2 (hu) 2013-07-19 2021-08-30 Boehringer Ingelheim Vetmedica Gmbh Éterezett ciklodextrin-származékokat tartalmazó, tartósított, folyékony, vizes gyógyászati készítmény
ES2883448T3 (es) 2013-12-04 2021-12-07 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmacéuticas mejoradas de pimobendán
US10537570B2 (en) * 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
EA039250B1 (ru) * 2016-06-01 2021-12-23 Бёрингер Ингельхайм Ветмедика Гмбх Применение пимобендана для уменьшения размера сердца и замедления начала клинических симптомов у пациентов с асимптоматической сердечной недостаточностью вследствие митрального порока сердца
WO2022073954A1 (en) 2020-10-08 2022-04-14 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan in the anaesthesia of non-human mammals
US20240390317A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8101067A1 (es) 1978-08-25 1980-12-01 Thomae Gmbh Dr K Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona
GB8400863D0 (en) * 1984-01-13 1984-02-15 Smith Kline French Lab Chemical compounds
ES2031821T3 (es) * 1985-10-17 1993-01-01 Smith Kline & French Laboratories Limited Procedimiento para preparar derivados de 4(4-oxo-1,4-dihidropiridin-1-il)fenilo.
US4868182A (en) 1986-11-05 1989-09-19 Merrell Dow Pharmaceuticals Inc. Enhancement of prazosin
DE3804490A1 (de) * 1988-02-12 1989-08-24 Heumann Pharma Gmbh & Co Substituierte 6-phenyldihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB8824458D0 (en) 1988-10-19 1988-11-23 Orion Yhtymae Oy Substituted pyridazinones
GB8903130D0 (en) 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
GB2251615B (en) 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
EP1430140B1 (en) * 2001-08-01 2010-09-15 University of Utah N-terminally truncated isoforms of pde3a cyclic phosphodiesterases
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure

Also Published As

Publication number Publication date
CN101309685A (zh) 2008-11-19
HUE033546T2 (hu) 2017-12-28
WO2007054514A2 (en) 2007-05-18
EP3210605A1 (en) 2017-08-30
JP5312034B2 (ja) 2013-10-09
EP1951227A2 (en) 2008-08-06
AU2006310997B2 (en) 2013-01-10
WO2007054514A3 (en) 2007-09-07
AU2006310997A1 (en) 2007-05-18
US20070112010A1 (en) 2007-05-17
DK1951227T3 (en) 2017-07-10
ES2631879T3 (es) 2017-09-05
EP1951227B1 (en) 2017-04-12
JP2009515927A (ja) 2009-04-16
CN102784394A (zh) 2012-11-21
CA2629367C (en) 2016-05-03
PL1951227T3 (pl) 2017-09-29
US20100273807A1 (en) 2010-10-28
CA2629367A1 (en) 2007-05-18
TW200735874A (en) 2007-10-01

Similar Documents

Publication Publication Date Title
AR048588A1 (es) Uso de inhibidores de la fosfodiesterasa de tipo iii (pde iii) para la reduccion del tamano del corazon en mamiferos que padecen insuficiencia cardiaca
AR056800A1 (es) Uso de inhibidores de la pde iii para el tratamiento de la isuficiencia cardiaca asintomatica ( oculta )
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
BRPI0412343A (pt) derivados de piridazina e seu uso como agentes terapêuticos
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
UY28958A1 (es) Nuevos derivados de piridazin-3(2h)-ona
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
AR087241A2 (es) Derivados de 6-oh-4h-benzo[1,4]oxazin-3-ona para el tratamiento de la enfermedad pulmonar obstructiva cronica
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
BRPI0714908B8 (pt) derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende
MA31358B1 (fr) Méthodes de traitement du cancer à l'aide d'inhibiteurs de pi3k alpha à base de pyridopyrimidinone
UY27890A1 (es) Tratamiento terapeutico
JP2015536973A (ja) PDE4阻害剤とPI3δ阻害剤または二重PI3δ−γキナーゼ阻害剤とを含有する薬学的組成物
CL2021003034A1 (es) Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton
EA200201276A1 (ru) Производные арилметиламина для использования в качестве ингибиторов триптазы
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
Kassab Recent advances in targeting COX-2 for cancer therapy: a review
PE20241327A1 (es) Tratamiento de trastornos hepaticos con un agonista del thr-beta
DOP2025000099A (es) Enlazadores-cargas útiles de adc derivados de exatecán, composiciones farmacéuticas, y usos de los mismos
ES2215327T3 (es) Composicion de medicamento inmunomodulador.
ITMI20042475A1 (it) Uso di derivati tiazolidinonici come agenti terapeutici
ATE306267T1 (de) Kombinationsbehandlung bei akutem myokardinfarkt
ES2525931T3 (es) Composiciones y métodos para prevenir o tratar enfermedad inflamatoria intestinal
AR123872A1 (es) Comprimido de desintegración oral, procedimiento de preparación del mismo, procedimiento para prevenir o tratar enfermedades y uso del mismo
PT1408977E (pt) Terapia de combinacao para o tratamento de falha cardiaca

Legal Events

Date Code Title Description
FA Abandonment or withdrawal